A detailed history of Geode Capital Management, LLC transactions in Greenwich Life Sciences, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 127,689 shares of GLSI stock, worth $1.72 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
127,689
Previous 58,244 119.23%
Holding current value
$1.72 Million
Previous $1.16 Million 89.75%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$12.07 - $19.04 $838,201 - $1.32 Million
69,445 Added 119.23%
127,689 $2.2 Million
Q1 2024

May 13, 2024

BUY
$8.31 - $20.32 $94,966 - $232,216
11,428 Added 24.41%
58,244 $1.16 Million
Q4 2023

Feb 13, 2024

BUY
$7.77 - $12.3 $5,625 - $8,905
724 Added 1.57%
46,816 $492,000
Q3 2023

Nov 13, 2023

BUY
$8.41 - $10.66 $51,797 - $65,654
6,159 Added 15.42%
46,092 $407,000
Q4 2022

Feb 13, 2023

SELL
$9.04 - $16.88 $21,027 - $39,262
-2,326 Reduced 5.5%
39,933 $606,000
Q3 2022

Nov 14, 2022

BUY
$7.81 - $12.02 $9,996 - $15,385
1,280 Added 3.12%
42,259 $384,000
Q2 2022

Aug 12, 2022

SELL
$7.14 - $20.36 $205,153 - $585,003
-28,733 Reduced 41.22%
40,979 $347,000
Q1 2022

May 13, 2022

BUY
$16.3 - $24.65 $37,359 - $56,497
2,292 Added 3.4%
69,712 $1.37 Million
Q4 2021

Feb 11, 2022

BUY
$21.76 - $39.43 $228,501 - $414,054
10,501 Added 18.45%
67,420 $1.64 Million
Q3 2021

Nov 12, 2021

BUY
$38.65 - $46.11 $174,852 - $208,601
4,524 Added 8.63%
56,919 $2.22 Million
Q2 2021

Aug 13, 2021

BUY
$31.24 - $53.6 $1.18 Million - $2.03 Million
37,932 Added 262.27%
52,395 $2.35 Million
Q1 2021

May 12, 2021

BUY
$22.37 - $39.98 $166,499 - $297,571
7,443 Added 106.03%
14,463 $493,000
Q4 2020

Feb 12, 2021

BUY
$3.48 - $72.22 $24,429 - $506,984
7,020 New
7,020 $256,000

Others Institutions Holding GLSI

About Greenwich LifeSciences, Inc.


  • Ticker GLSI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,848,200
  • Market Cap $173M
  • Description
  • Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who ha...
More about GLSI
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.